TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22627678
Drug: Midostaurin 50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 50-mg twice-daily dose schedule
Study: 22627678
Drug: Midostaurin 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 100-mg twice-daily dose schedule
Study: 22627678
Drug: Midostaurin in
Normalized name: Product containing midostaurin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin in combination with standard chemotherapy
Study: 22633255
Drug: First model
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First model (age, duration of infertility, insulin/glucose ratio)
Study: 22633265
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists with serum P levels ≥ 2.0 ng/mL
Study: 22633265
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists with serum P levels <1.5 ng/mL
Study: 22633265
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists with serum P levels 1.5-1.99 ng/mL
Study: 22633322
Drug: Na-ASP-2 vaccine
Normalized name: sodium lauroyl aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-ASP-2 vaccine
Study: 22634437
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine 160U (only for children)
Study: 22634437
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine 320U
Study: 22634437
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine 640U
Study: 22634437
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (all doses)
Study: 22634437
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (one dose)
Study: 22638007
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT) for depression
Study: 22639293
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion (20% Intralipid at 90 ml/h)
Study: 22639293
Drug: Glycerol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol infusion (2.25 g/100 ml at 90 ml/h)
Study: 22640652
Drug: Seasonal flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal flu vaccine (SFV) - 1 dose, Mutagrip®
Study: 22640652
Drug: A/H1N1 flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/H1N1 flu vaccine (HFV) - 2 doses at a 3-week interval, Panenza®
Study: 22640652
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (SFV and HFV)
Study: 22643560
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks) and Erlotinib (150 mg daily)
Study: 22645182
Drug: Dasatinib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (first-line therapy)
Study: 22647431
Drug: Etanercept therapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept therapy (anti-TNF) for 12 weeks
Study: 22647519
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion of adenosine via the forearm vein (140 μg/min/kg)
Study: 22647519
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion of adenosine via the femoral vein (140 μg/min/kg)
Study: 22647519
Drug: Intracoronary bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus injection of adenosine
Study: 22647519
Drug: Additional bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional bolus injection of adenosine during IV infusion
Study: 22647519
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes of adenosine infusion (femoral vs. forearm)
Study: 22648179
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing of trastuzumab emtansine (T-DM1) at 2.4 mg/kg
Study: 22648179
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing of trastuzumab emtansine (T-DM1)
Study: 22651703
Drug: Vemurafenib and
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib and GDC-0973 combination
Study: 22651703
Drug: Vemurafenib in
Normalized name: Product containing vemurafenib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib in mice with drug-resistant A375 xenografts
Study: 22651703
Drug: Vemurafenib and
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib and GDC-0973 combination efficacy
Study: 22652104
Drug: 3-dimensional conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dimensional conformal external beam accelerated partial breast irradiation (3D-APBI) at 32 Gy delivered in 8 twice-daily fractions
Study: 22653976
Drug: Bortezomib combined
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib combined with chemotherapy
Study: 22653976
Drug: Bortezomib combined
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib combined with chemotherapy and prophylactic antibiotics (vancomycin, levofloxacin, voriconazole)
Study: 22655593
Drug: Encapsulated cell
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated cell biodelivery (ECB) implants delivering nerve growth factor (NGF)
Study: 22656234
Drug: Rituximab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (750 mg/m(2) on days 1, 8, 15, and 22) and Temozolomide (150 mg/m(2) days 1-7 and 15-21) followed by consolidation Temozolomide (150-200 mg/m(2) × 5/28 days) and maintenance with Methylprednisolone (1 g IV every 28 days) until progression
Study: 22658128
Drug: Anti-PD-L1 antibody
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-L1 antibody (0.3 to 10 mg/kg, administered every 14 days in 6-week cycles for up to 16 cycles)
Study: 22658128
Drug: Anti-PD-L1 antibody
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-L1 antibody
Study: 22658254
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration before primary PCI
Study: 22658254
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration before primary PCI
Study: 22659939
Drug: VO2peak >27.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VO2peak >27.3 ml/kg/min
Study: 22659939
Drug: VO2peak ≤27.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VO2peak ≤27.3 ml/kg/min
Study: 22661474
Drug: Ranibizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (monthly intravitreal injections)
Study: 22662137
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies against EV71 in infants at 2 months
Study: 22662137
Drug: Maternal antibody
Normalized name: Maternal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibody titers
Study: 22662137
Drug: Seropositivity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seropositivity of EV71 antibody in infants
Study: 22664059
Drug: Flavopiridol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol (100 mg/m2 IV, 24 h infusion) and Cisplatin (60 mg/m2 IV)
Study: 22665938
Drug: CRd (carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRd (carfilzomib 36 mg/m2, lenalidomide 25 mg/d, dexamethasone 40/20 mg)
Study: 22668067
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg (single dose on day 1 and once daily on days 3-7)
Study: 22668067
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg (single dose and once-daily doses for 5 days)
Study: 22670903
Drug: Vismodegib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (150 mg oral daily)
Study: 22674435
Drug: L19-TNF ILP
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: L19-TNF ILP at 325 µg
Study: 22674435
Drug: L19-TNF ILP
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: L19-TNF ILP at 650 µg
Study: 22676070
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 to 6 mg/day) for 6 months
Study: 22676070
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 to 6 mg/day) for 12 months
Study: 22676070
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 to 6 mg/day)
Study: 22676070
Drug: Risperidone maintenance
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone maintenance treatment
Study: 22677155
Drug: Lenalidomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (20 mg) plus rituximab
Study: 22681919
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg dose)
Study: 22682146
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (Norditropin®)
Study: 22685225
Drug: Secondary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary prevention treatment for children diagnosed with RHD
Study: 22693172
Drug: Anti-Müllerian hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-Müllerian hormone (AMH) at a cut-off value of 20 pmol/l
Study: 22693229
Drug: Initial study
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial study vaccination with HIV load ≤400 copies/mL
Study: 22695105
Drug: 10 μg vitamin
Normalized name: Vitamin G
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 μg vitamin D3 from fish oil capsules
Study: 22695105
Drug: Multivitamin tablets
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multivitamin tablets
Study: 22695254
Drug: Ridaforolimus (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus (50 mg intravenous once weekly)
Study: 22696176
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg inhaled salbutamol
Study: 22698649
Drug: Mass eradication
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass eradication of H pylori infection (1-week clarithromycin-based triple therapy followed by 10-day levofloxacin-based triple therapy for treatment failures)
Study: 22699667
Drug: Oral cGVHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cGVHD (defined by NIH scale >2 points)
Study: 22700780
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of auscultation and LUS
Study: 22701542
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised exercise for two weeks
Study: 22701615
Drug: Vandetanib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (100 mg, 200 mg, or 300 mg daily) combined with cetuximab and irinotecan
Study: 22707516
Drug: Bevacizumab, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, 5 mg/kg or 10 mg/kg every 2 weeks
Study: 22708895
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide loading dose of 200 mg
Study: 22708895
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide loading dose of 300 mg
Study: 22708895
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide loading dose of 400 mg
Study: 22713099
Drug: Ethinylestradiol 30μg-drospirenone
Normalized name: drospirenone and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 30μg-drospirenone 3mg plus metformin 1700 mg daily for 6 months
Study: 25886678
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for 16 weeks
Study: 22717743
Drug: AAV1-LPL(S447X) gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec) administered at 3 × 10(11) gc kg(-1) for cohorts 1 (n=2) and 2 (n=4) and 1 × 10(12) gc kg(-1) for cohort 3 (n=8). Immunosuppressants were also given to cohorts 2 and 3 for 12 weeks.
Study: 22717743
Drug: AAV1-LPL(S447X) gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec)
Study: 22719881
Drug: Bevacizumab monotherapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression
Study: 22721971
Drug: Rapamycin/IL-2 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin/IL-2 combination therapy
Study: 22722717
Drug: Doxorubicin-eluting beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-eluting beads (DEB) in transarterial chemoembolization (TACE), 100-300 μm beads loaded with ≤100 mg doxorubicin, up to four sessions within 6 months.
Study: 22722755
Drug: Enzyme-linked immunospot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-linked immunospot assay (within 2 years of drug reaction)
Study: 22722778
Drug: ACTH gel
Normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH gel (80 units subcutaneously twice weekly for 6 months)
Study: 24009220
Drug: ACTH gel
Normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH gel
Study: 22723305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of independent baseline predictors.
Study: 22723326
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapies (AET; leuprolide, tamoxifen, aromatase inhibitors)
Study: 22723441
Drug: Insulin activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin activation of fatty acid uptake
Study: 22727048
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy with insulin detemir / insulin aspart
Study: 22727048
Drug: Human NPH
Normalized name: INSULIN HUMAN NPH 100 UNIT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human NPH insulin / human regular insulin
Study: 22730482
Drug: Soluble tumour
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble tumour necrosis factor receptor (sTNFR-1)
Study: 22731653
Drug: Eszopiclone 1
Normalized name: eszopiclone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 1 mg (elderly)
Study: 22731653
Drug: Eszopiclone 2
Normalized name: eszopiclone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 2 mg (elderly)
Study: 22731653
Drug: Eszopiclone 2
Normalized name: eszopiclone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 2 mg (nonelderly)
Study: 22731653
Drug: Eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 3 mg (nonelderly)
Study: 22731653
Drug: Eszopiclone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone (1 mg or 2 mg for elderly; 2 mg or 3 mg for nonelderly)
Study: 22732334
Drug: HX575 (biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX575 (biosimilar epoetin-α) administered intravenously aiming for hemoglobin (Hb) target of 10 - 12 g/dl
Study: 22733017
Drug: Anti-plasma cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-plasma cell therapy
Study: 22733373
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg IV 30 min before chemotherapy
Study: 22734012
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² plus cisplatin 60 mg/m² (day 1), followed by oral capecitabine 1875 mg/m² divided into two doses (days 1-14) every 3 weeks; three cycles preoperatively and three cycles postoperatively
Study: 22734119
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus acupuncture treatment
Study: 22734817
Drug: Anemia (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia (defined as Hb <11.0 g/dl in children <5 years or <11.5 g/dl in children 5-12 years)
Study: 22735035
Drug: Exenatide administration
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide administration for an average of 84 ± 5 days
Study: 22735035
Drug: Exenatide administration
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide administration
Study: 22736604
Drug: Novel cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel cancer cell vaccine for prostate cancer
Study: 22736604
Drug: Intravenous aciclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aciclovir and dexamethasone
Study: 22742742
Drug: Certoparin 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 3,000 IU i.v. with additional titration steps of 600 IU and/or continuous infusion if necessary
Study: 22742881
Drug: IV busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV busulfan (0.8-1.2 mg/kg) administered four times daily for 4 days
Study: 22742881
Drug: Oral busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral busulfan (1.45-1.55 mg/kg) administered four times daily for 4 days
Study: 22744195
Drug: PEG-3350 mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-3350 mixed with 1.9 L of Gatorade
Study: 22748805
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acid (PUFA) supplementation (3 g/day)
Study: 22750015
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D(3) supplementation (0 to 4000 IU/d)
Study: 22751081
Drug: Natrelle Style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natrelle Style 410 implants
Study: 22751595
Drug: IA etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IA etanercept injections (12.5 mg, 4 injections every 2 weeks)
Study: 22752026
Drug: Insulin-mediated myocardial
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-mediated myocardial glucose disposal assessed with 2-deoxy-2-[(18)F]fluoroglucose PET.
Study: 22759444
Drug: Progressors (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressors (n = 39) defined as those with serial LAVI change ≥3.5 mL/m(2) and baseline LAVI between 20 and 34 mL/m(2)
Study: 22760567
Drug: Insulin (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (during hyperinsulinemic euglycemic clamp)
Study: 22761257
Drug: Leukotriene B4
Normalized name: Leukotriene B4
DrugBank: Leukotriene B4 (DB12961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene B4 (LTB4) at 10 ng/ml in OSA patient monocytes
Study: 22761653
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg daily) and IGRT (50 Gy)
Study: 22762314
Drug: Eltrombopag (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (50 mg daily, increased to 150 mg as needed for 12 weeks)
Study: 22763609
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² intravenously every 21 days until progression or unacceptable toxicity
Study: 22766223
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) at 100 μg/day for 28 days
Study: 22766247
Drug: MF59-adjuvanted A/H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted A/H1N1 influenza vaccine, Focetria
Study: 22766773
Drug: Enzastaurin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (500 mg QD, 250 mg BID, 375 mg BID, 500 mg BID, 750 mg BID) in combination with Bevacizumab (5 mg/kg every 2 weeks, 10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks)
Study: 22766773
Drug: Enzastaurin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (750 mg BID) in combination with any tested dose/schedule of Bevacizumab
Study: 22767640
Drug: B lymphocyte
Normalized name: B lymphocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: B lymphocyte depletion therapy (iv rituximab 1 g on days 1 and 15 after 125 mg iv methylprednisolone)
Study: 22768052
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine (10 µg) with Alhydrogel